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Pituitary metastases are unusual complications of malignancies. In about only 2% of patients they origin from
colorectal cancer (CRC), with breast and lung as the most common primary tumors. Nevertheless, some authors
reported a recent increase of the incidence of metastases in infrequent sites, such as brain or bone, arising from
gastrointestinal cancers, probably due to the expanded treatment options and the resulting improved survival.
Here, we report the case of a 54-year old woman diagnosed with lung metastases from rectal cancer, who, after
several cycles of radio- and chemotherapy, presented symptoms and signs of pituitary disfunction (i.e. diabetes
insipidus, hypothyroidism and diplopy). The diagnosis of pituitary metastasis from rectal cancer was histologically
confirmed after surgery.
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Metastases to the pituitary gland are rare complications
of advanced cancer. Data from a large number of autop-
sies show that pituitary metastases are present in 1–3.6%
of patients with malignancies (McCormick et al. 1989).
Breast cancer is the most common tumor metastasizing
to the pituitary gland, followed by lung, prostate, renal
cell and gastrointestinal cancers; lymphoma, leukemia,
thyroid carcinoma, and plasmocytoma have also been
described (Fassett and Couldwell 2004). Brain metastases
from CRC are very uncommon; in a recent analysis a cu-
mulative incidence of 1.2% was reported. In particular,
CRC is a rare cause of metastases to the pituitary gland
(Schouten et al. 2002). In a series of 380 cases it was the
primary tumor in only 2.4% of such cases (9 patients)
(Komninos et al. 2004). Before the advent of modern
systemic therapies most CRC patients lived for only few
months. Late onset metastases in brain or central ner-
vous system rarely developed and patients died before
such metastases could occur. Recent therapies allow lon-
ger disease-free intervals and better overall survival; this
probably explains the current increase in the incidence* Correspondence: g.tomasello@ospedale.cremona.it
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in any medium, provided the original work is pof metastases from colorectal cancers in uncommon
sites, such as brain and/or bone (Go et al. 2011). Here
we report an unusual case of a young-adult woman, who
developed pituitary metastases from rectal cancer 4 years
after the resection of the primary tumor and following
prior neo- and adjuvant treatments.Case description
A 54-year old caucasian woman was admitted to the
radiotherapy division of our hospital in September 2007,
with new diagnosis of adenocarcinoma of the rectum
(clinical stage T3, N2, M1 [lung]). The patient, after
neoadjuvant radio-chemotherapy (50 Gy totally delivered
to the posterior pelvis from September 27th to Novem-
ber 16th associated with Oxaliplatin 75 mg/mq weekly +
5FU 225 mg/mq as a continuous intravenous infusion
from September 27th to October 5th, early interrupted
after 2 weeks for severe diarrhea and fever), underwent
an abdomino-perineal resection of the rectum in January
2008, followed by adjuvant chemotherapy with FOLFOX4
scheme (12 cycles, from February 27th to September 3rd).
A CT (computed tomography) scan of her chest re-
vealed a size reduction of the two pulmonary lesions
in September 2008.
Subsequent controls (TC and PET scans) showed pul-
monary progression of disease and tumor markers increaseOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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July 2009. The patient agreed to start a new line of chemo-
therapy in April 2010 only, after a new CT scan carried
out in March 2010 showed further increase in size of the
pulmonary lesions. Irinotecan 200 mg/m2 and Bevacizumab
7.5 mg/Kg every 3 weeks were administered from April
9th to June 7th (Irinotecan early stopped for gastrointes-
tinal toxicity and patient’s refusal) followed by Bevacizumab
alone at a dose of 5 mg/Kg bi-weekly for ten cycles from
July until December, with instrumental evidence of stable
disease until January 2011, when a CT of her chest and a
PET scan revealed a new progression of disease in this site.
For this reason, she started a new treatment with
Raltitrexed 3 mg/mq q3w in January 2011, early inter-
rupted after 1 cycle for severe bone marrow toxicity.
The patient decided to refuse any further treatment
until April 2011, when she was admitted to the Oncol-
ogy division of our hospital asking for second medical
opinion and, after an instrumental restaging, she was en-
rolled in a clinical trial in May 2011. Because of her wild-
type k-ras mutational status, she received Cetuximab
361 mg weekly, for 8 cycles until July 2011, when a re-
staging CT scan showed the appearance of a new pul-
monary lesion. Therefore, patient was offered a new
chemotherapy with XELOX scheme (Oxaliplatin 141 mg,
day 1, Capecitabine 2500 mg day 2–15 q3w) in August
2011, suspended after the 3rd cycle for moderate neuro-
toxicity and severe diarrhea. The patient underwent an in-
strumental re-evaluation with thoraco-abdominal CT scan
in October 2011, which evidenced dimensional increase of
pulmonary lesions.
Taking into consideration the previous chemotherapy
toxicities and the patient’s reluctance to receiving new
potentially toxic agents, we offered a palliative treatment
with cyclophosphamide and methotrexate at low con-
tinuative doses, which patient started in November
2011. The following CT scan revealed stable disease in
February 2012, but the patient decided to interrupt
treatment for severe asthenia and mucositis, until April
2012, when, we decided to administer Mitomycin C at
the dose of 6 mg/m2 every 4 weeks, after the evidence
of further increase in size of the pulmonary lesions.
The patient, after the third cycle of therapy, complained
poliuria and polidipsia, but there was no evidence of plas-
matic and urinary osmolites alteration. For this reason, we
planned a restaging CT, including brain imaging.
Few days later, she was admitted to the Neurosurgery
Unit reporting, in addition to polidipsia and poliuria, re-
current episodes of headache and vomit, associated with
diplopy, decrease in visual acuity and ophtalmoplegy at
the right eye. Brain CT scan and magnetic resonance
imaging revealed the presence of a voluminous endo-
sovrasellar lesion (cranio-caudal diameter: 25 mm; trasversal
diameter: 20 mm), compressing the optic chiasm extendedto the third ventricle and to both cavernous sinuses, in
particular to the right one (Figures 1 and 2). Hyponatremia
(126 mEq/L; normal range 135–145 mEq/L), low urine spe-
cific weight (1001; normal range 1014–1030), subclinical
hypothyroidism (TSH 0.0010 μUI/ml; normal range
0.400-4.200 μUI/ml), were also found, confirming the
diagnosis of pituitary failure (central diabetes insipidus
and central hypothyroidism). In order to improve the pa-
tient’s clinical conditions (diabetes insipidus, in particular),
therapy with desmopressin acetate, 1 puff twice a day in
both nostrils was started. This therapy promptly improved
the symptoms of diabetes insipidus (we observed decrease
of polydipsia and polyuria with normalization of urine
specific weight in 4 days) but the severe diplopia and other
visual field impairments such as hemianopsia, cephalea
and vomit seriously compromised patient’s quality of life.
Therefore, the lesion was surgically removed and histo-
logical examination confirmed the diagnosis of adeno-
carcinoma of intestinal origin (Figure 3).
Despite the improvement of neurological symptoms
after surgery, the patient died of respiratory complica-
tions as a result of the lung disease involvement 8 days
later, in August 2012.
Discussion
The pituitary gland is an uncommon site for metastases,
in particular from CRC. Breast and lung cancers are the
most common diseases spreading to this site (Morita
et al. 1998). Teears and Silverman analysed 88 patients
with pituitary metastases and noticed that breast and
lung were the most frequent sites of the primary tumor
(40% and 33%, respectively), whereas 2% of patients only
presented CRC as primary site of disease (Teears and
Silverman 1975). In the absence of specific series in the
literature, the incidence of rectal cancer metastasizing to
the pituitary is certainly even lower.
The widest review of literature about pituitary metas-
tases including 380 patients, mentions 9 cases only of
primary localization in colorectal site (Komninos et al.
2004). These data confirm the rarity of our report.
Recent studies reveal that the majority of pituitary me-
tastases occur in the posterior lobe. The same work by
Teears and coll., reported that 57% of the lesions are lo-
calized to the posterior pituitary alone, 13% to the anter-
ior pituitary alone, 12% to both lobes and the remaining
to the capsule or stalk (Teears and Silverman 1975).
The majority of pituitary metastases are clinically silent.
When the patient is symptomatic, the most common
clinical presentation seems to be diabetes insipidus (DI)
(45.2%), reflecting a predominance of metastases to the
posterior lobe (Sioutos et al. 1996). Other reported symp-
toms are ophtalmoplegia, headache, visual field defects
and anterior pituitary disfunction (Nelson et al. 1987).
Additionally, DI is more common in patients with pituitary
Figure 1 Coronal T2WI MR. Intra and suprasellar “snowman-shaped” mass showing mixed intensity signal with hypointense focus of
hemorrhage present within the lesion (arrow). The tumor invades the cavernous sinus (arrowhead).
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1998). In a series of 190 cases of symptomatic pituitary
metastasis, DI was reported in 45.2% of patients, optic
nerve impairment in 27.9% and anterior pituitary insuffi-
ciency in 23.6% (Komninos et al. 2004). Twenty-oneA B
Figure 2 Coronal (A) and Sagittal (B) T1WI MR after contrast medium
enhancement involving the infundibular stalk (curved arrow) and extendin
sella (arrow).percent of patients developed other cranial nerves defects
such as 3rd, 4th, and 6th palsy.
In about 25% of the cases the diagnosis is made after
laboratory evidence of anterior pituitary failure (Freda
and Post 1999).administration. Large pituitary mass with inhomogeneous
g into suprasellar cistern. The mass expands and deepens the bony
Figure 3 Histological examination of the pituitary lesion surgically removed. A: Primary site of disease (colorectal tissue; hematoxylin-eosin stain).
B: Adenohypophyseal parenchimal tissue with evidence of metastatic cells from adenocarcinoma. On the left side: Adenohypophyseal tissue; On the
right side: Clusters of neoplastic glandular cells (hematoxylin-eosin stain). C: Metastatic adenocarcinomatous cells invading adenohypophyseal
parenchimal tissue. No evidence of immunocoloration for CDX-2 (caudal type homebox transcription factor 2) into adenohypophyseal parenchimal
tissue (upper right corner of the image); positive nuclear CDX-2 immunocoloration found in clusters of metastatic adenocarcinoma cells agreeing with
the rectal origin of the lesion. D: Metastatic adenocarcinomatous cells invading adenohypophyseal parenchimal tissue. No evidence of
immunocoloration for cytokeratin 20 into adenohypophyseal tissue; positive cytokeratin 20 immunocoloration found in clusters of metastatic
adenocarcinomatous cells.
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guishing adenoma from metatasis. High resolution CT
and MRI are the most sensitive exams. CT usually shows
a hyperdense or isodense mass, enhancing homogeneously
or non-homogeneously (if cystic degeneration, hemor-
rhage, or necrosis co-exist) in contrast images. MRI may
demonstrate an isointense or hypointense mass on T1
weighted images, with a usually high-intensity signal on
T2 weighted images, homogeneously enhancing post-
gadolinium, as well as absence of high-signal intensity
from the posterior lobe on T1. Neither of the imaging
findings is highly specific and allows to make a correct
diagnosis (Schubiger and Haller 1992). The definitive
diagnosis of metastatic involvement is always based on
histological evaluation, allowing to distinguish from pi-
tuitary primary lesions (Go et al. 2011).
Benign lesions more often are functioning masses, fre-
quently producing ACTH and prolactin; on the other
hand, metastases might cause disfunction of the pituitary
gland and compression of the near anatomic structures
(Max et al. 1981).
Treatment, mostly palliative, depends on the symp-
toms. Surgical exploration and decompression, alone orcombined with radiation, is often necessary when supra-
sellar extension causes progressive deterioration in vision
and/or pain (Branch and Laws 1987). In our case, tumor
debulking allowed to improve the local symptoms, espe-
cially headache and visual field defects such as diplopia
and hemianopsia.
Generally, the surgical approach, the completeness of
the resection, and an aggressive treatment (surgery plus
local radiation) are associated with better symptom relief
but do not affect survival rates; in fact, prognosis of pa-
tients with MPs is usually poor, with a life expectancy of
few months after diagnosis (Komninos et al. 2004).
The peculiarity of the case described above is not only
represented by the unusual site of metastasis from rectal
cancer, but also by the long history of treatments re-
ceived by our patient.
Recent studies show that the expanded treatment op-
tions and the consequent improved survival for patients
with metastatic CRC are associated with an increased in-
cidence of metastases at uncommon sites (Sundermeyer
et al. 2005). A comprehensive review on the incidence,
prevalence, epidemiology, risk factors, management, and
prognosis of brain metastases arising from esophageal,
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cancer reported that brain metastases are found in 1% of
colorectal cancer, 1.2% of esophageal cancer, 0.62% of gas-
tric cancer, and 0.33% of pancreatic cancer cases. Survival
in patients with brain metastases from gastrointestinal tu-
mors was found to be inferior compared with breast, lung
or kidney. Authors concluded that, although early treat-
ment has been linked to prolonged survival and improved
quality of life, brain metastases represent a late manifest-
ation of gastrointestinal cancers and remain an ominous
sign (Go et al. 2011).
Sundermeyer and colleagues evaluated patients with
metastatic CRC from 1993 to 2002 at the Fox Chase
Cancer Center, collecting date of diagnosis/metastasis,
primary tumor site, therapeutic agents received, survival,
and site(s) of metastases. The data demonstrate that the
incidence of bone and brain metastases in patients with
CRC is more common than previously reported and is
associated with the administration of multiple systemic
treatments (Sundermeyer et al. 2005).
In conclusion, here we presented the case of a patient
affected by metastatic rectal cancer, with a large sellar
mass and a long history of oncological treatments.
The rarity of involvement of the pituitary gland from
rectal cancer made diagnosis challenging and the histo-
logical evaluation helped to confirm the intestinal origin
of the lesion. This metastatic event is very uncommon
making almost impossible to perform prospective clinical
trials specifically designed to compare different treatment
approaches. Thus, only a greater awareness of the problem
along with a more accurate and timely diagnosis, will lead
to choose the best therapies suitable to the specific patient
and in turn improve overall prognosis.
Although infrequently, metastatic involvement of the
pituitary gland from colorectal cancer can be found and
it might become increasingly common in the next future
as a result of the expanded treatment options and the
consequent improved patients’ survival.
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